Ovid Therapeutics (OVID) Retained Earnings (2020 - 2025)
Historic Retained Earnings for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to -$331.4 million.
- Ovid Therapeutics' Retained Earnings fell 1232.18% to -$331.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$331.4 million, marking a year-over-year decrease of 1232.18%. This contributed to the annual value of -$304.3 million for FY2024, which is 951.33% down from last year.
- According to the latest figures from Q3 2025, Ovid Therapeutics' Retained Earnings is -$331.4 million, which was down 1232.18% from -$319.2 million recorded in Q2 2025.
- Ovid Therapeutics' 5-year Retained Earnings high stood at -$118.2 million for Q1 2021, and its period low was -$331.4 million during Q3 2025.
- In the last 5 years, Ovid Therapeutics' Retained Earnings had a median value of -$251.3 million in 2023 and averaged -$240.2 million.
- Its Retained Earnings has fluctuated over the past 5 years, first soared by 4931.75% in 2021, then crashed by 5864.99% in 2022.
- Quarter analysis of 5 years shows Ovid Therapeutics' Retained Earnings stood at -$171.4 million in 2021, then plummeted by 31.61% to -$225.5 million in 2022, then decreased by 23.21% to -$277.9 million in 2023, then fell by 9.51% to -$304.3 million in 2024, then dropped by 8.91% to -$331.4 million in 2025.
- Its Retained Earnings was -$331.4 million in Q3 2025, compared to -$319.2 million in Q2 2025 and -$314.5 million in Q1 2025.